Omalizumab for chronic urticaria

New England Journal of Medicine

Volumn 368, Issue 26, 2013, Pages 2527-2530

  Wu, Keith ^a   Long, Heather ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OMALIZUMAB; PLACEBO; ANTIALLERGIC AGENT; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ASTHMA; CHRONIC URTICARIA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LETTER; LONGITUDINAL STUDY; PRIORITY JOURNAL; RHINITIS; TREATMENT OUTCOME; FEMALE; MALE; NOTE; PRURITUS; URTICARIA;

ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE; PRURITUS; URTICARIA;

EID: 84879363392     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1305687     Document Type: Letter

References (3)

1. Maurer M, Rosén K, Hsieh H-J, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013;368:924-35.
2. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy 2009;39:788-97.
3. Berger W, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 2003;91:182-8. (Pubitemid 36999479)